http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Valeritas Reports Fourth Quarter and Full Year 2018 Financial Results
-
Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Switching to Valeritas’ V-Go® Wearable Insulin Delivery Device from Insulin Pen Devices for Basal-Bolus Therapy Improved Glycemic Control with Less Insulin
-
Valeritas to Present at Upcoming Investor Conferences
-
Valeritas to Report Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019
-
Valeritas (VLRX) Announces V-Go Received Preferred Status on OptumRx Formularies
-
Valeritas Announces V-Go® Received Preferred Status on OptumRx Formularies
-
Valeritas Announces V-Go® is Preferred on Humana Part D Formularies
-
Valeritas CEO John Timberlake to Participate as a Panelist on “Exploring Innovation in Diabetes Tech,” at DeviceTalks West Conference
-
Study Supports Valeritas’ V-Go® Can Improve Glycemic Control in Type 2 Patients When Using an Easy to Follow Physician-Driven Insulin Titration Algorithm
-
Valeritas (VLRX) Prices 75M Unit Offering at $0.48/Unit
-
Valeritas Announces Pricing of $36 Million Public Offering
-
Valeritas Signs Exclusive Middle East Distribution Agreement with Julphar
-
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical and Economic Benefits Across Established BMI Strata in Patients with Type 2 Diabetes Including Those Overweight and
-
Valeritas Reports Record Revenue for the Third Quarter 2018
-
Valeritas to Report Third Quarter 2018 Results November 9, 2018
-
Valeritas Wins Fifth Consecutive Cardinal Health Supply Chain Excellence Award
-
Valeritas Expects to Report Record Revenue for Third Quarter 2018
-
Valeritas is a Contributing Supporter of the Interactive Insulin Workshop at MEDS East Summit
-
Persistent Use of Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Significant Clinical & Economic Benefits Compared to Conventional Insulin Delivery in Patients with Type 2 Diab
-
Valeritas’ V-Go® Demonstrates Benefits Versus Multiple Daily Injections in Patients with Type 2 Diabetes
-
Valeritas Begins Medical Device Registration Process in China for Its V-Go® Wearable Insulin Delivery Device
-
Valeritas Announces that V-Go® Insulin Delivery Device Has Launched in Australia
-
Valeritas Reports Record Second Quarter Revenue with 36% Year-over-Year Growth
-
Valeritas Announces V-Go® Distribution Agreement in Czech Republic and Slovakia
-
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical Benefits in Patients with Uncontrolled Type 2 Diabetes Previously Treated with Multiple Daily Injections
-
Valeritas Announces that V-Go® Insulin Delivery is Now Available in New Zealand
-
Valeritas, Makers of V-Go® Insulin Delivery, is a Contributing Supporter of the Interactive Insulin Workshop at Two MEDS Conferences
-
Valeritas to Report Second Quarter 2018 Results August 7, 2018
-
Valeritas ENABLE Study Demonstrates Significant Clinical Benefits of V-Go in Patients with Type 2 Diabetes Who Switched from Insulin Pens and Syringes
-
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Positive Clinical and Economic Benefits in Patients with Type 2 Diabetes
-
Valeritas Announces V-Go® Distribution Agreement in Austria and Germany
-
Valeritas (VLRX) Reports Positive Clinical Results Across Two New Studies Evaluating V-Go Wearable Insulin Delivery Device
-
Valeritas Announces Positive Clinical Results Across Two New Studies Evaluating V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes
-
Valeritas’ V-Go® Wearable Insulin Delivery Device Results in Clinical Benefits Sustained Over Time in Patients with Diabetes
-
Valeritas Reports Record First Quarter Revenue with 32% Year-over-Year Growth and Gross Margins Expand to Record 47.6%
-
Valeritas to Report First Quarter 2018 Results on May 9, 2018
-
Valeritas Presented New Data Demonstrating use of V-Go® Wearable Insulin Delivery Device Results in More Patients with Type 2 Diabetes Achieving Blood Glucose Targets
-
Valeritas (VLRX) Prices 13.7M Common Stock Offering at $1.75/Share
-
Valeritas Announces Pricing of $24 Million Public Offering of Common Stock
-
Valeritas Teams with Glooko as its Preferred Data Management Partner for V-Go® SIM™
-
Valeritas (VLRX) Announces V-Go Distribution Agreement in Australia and New Zealand (Earlier)
-
Valeritas Announces V-Go® Distribution Agreement in Australia and New Zealand
-
Valeritas to Present at Upcoming Investor Conferences
-
Valeritas Reports Fourth Quarter and Full Year 2017 Financial Results
-
Valeritas Announces V-Go® Distribution Agreement in Italy with Movi SpA
-
Valeritas Announces V-Go® Distribution Agreement in Italy with Movi SpA
-
Valeritas Presents Data Demonstrating V-Go® Wearable Insulin Delivery Device Significantly Reduces A1C and Insulin Requirements in Patients with Type 2 Diabetes, When Combined with a Simplified Ins..
-
Valeritas Presents Data Demonstrating V-Go® Wearable Insulin Delivery Device Significantly Reduces A1C and Insulin Requirements in Patients with Type 2 Diabetes, When Combined with a Simplified Insu
-
Valeritas to Report Fourth Quarter 2017 Results February 26, 2018
